Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the main cause of de...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Genlong, Yang, Xiaolei, Zhan, Ge, Wang, Xin, Gao, Jinghan, Zhao, Yong, Wang, Xinying, Li, Jiatian, Pan, Zhenwei, Xia, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616207/
https://www.ncbi.nlm.nih.gov/pubmed/36313361
http://dx.doi.org/10.3389/fphar.2022.988408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616207/
https://www.ncbi.nlm.nih.gov/pubmed/36313361
http://dx.doi.org/10.3389/fphar.2022.988408

Ejemplares similares